scholarly journals Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype

Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 98598-98608 ◽  
Author(s):  
Feng Li ◽  
Olga V. Glinskii ◽  
Brian P. Mooney ◽  
Kate Rittenhouse-Olson ◽  
Kenneth J. Pienta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cell Surface ◽  
Cancer Stem Cell ◽  
Cancer Cells ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Proteome Profiling ◽  
Potential Link

scholarly journals Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells

2016 ◽  
Vol 36 (12) ◽  
pp. 6367-6380 ◽  
Author(s):  
PEI-HSUN TSAI ◽  
CHIA-HSIUNG CHENG ◽  
CHUN-YU LIN ◽  
YING-TANG HUANG ◽  
LUNG-TA LEE ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cancer Cells ◽  
Metastatic Potential ◽  
Prostate Cancer Cells ◽  
Dietary Flavonoids

scholarly journals Engineering A11 Minibody-Conjugated, Polypeptide-Based Gold Nanoshells for Prostate Stem Cell Antigen (PSCA)–Targeted Photothermal Therapy

2016 ◽  
Vol 22 (1) ◽  
pp. 26-35 ◽  
Author(s):  
Kristine M. Mayle ◽  
Kathryn R. Dern ◽  
Vincent K. Wong ◽  
Kevin Y. Chen ◽  
Shijun Sung ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Cells ◽  
Photothermal Therapy ◽  
Metastatic Prostate Cancer ◽  
Gold Nanoshells ◽  
Infrared Light ◽  
Prostate Stem Cell Antigen ◽  
Prostate Cancer Cells ◽  
Cell Antigen

Currently, there is no curative treatment for advanced metastatic prostate cancer, and options, such as chemotherapy, are often nonspecific, harming healthy cells and resulting in severe side effects. Attaching targeting ligands to agents used in anticancer therapies has been shown to improve efficacy and reduce nonspecific toxicity. Furthermore, the use of triggered therapies can enable spatial and temporal control over the treatment. Here, we combined an engineered prostate cancer–specific targeting ligand, the A11 minibody, with a novel photothermal therapy agent, polypeptide-based gold nanoshells, which generate heat in response to near-infrared light. We show that the A11 minibody strongly binds to the prostate stem cell antigen that is overexpressed on the surface of metastatic prostate cancer cells. Compared to nonconjugated gold nanoshells, our A11 minibody-conjugated gold nanoshell exhibited significant laser-induced, localized killing of prostate cancer cells in vitro. In addition, we improved upon a comprehensive heat transfer mathematical model that was previously developed by our laboratory. By relaxing some of the assumptions of our earlier model, we were able to generate more accurate predictions for this particular study. Our experimental and theoretical results demonstrate the potential of our novel minibody-conjugated gold nanoshells for metastatic prostate cancer therapy.

Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties

2012 ◽  
Vol 138 (4) ◽  
pp. 675-686 ◽  
Author(s):  
Linlin Zhang ◽  
Min Jiao ◽  
Lei Li ◽  
Dapeng Wu ◽  
Kaijie Wu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cancer Cells ◽  
Prostate Cancer Cells

scholarly journals Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Jeremy J. McGuire ◽  
Jeremy S. Frieling ◽  
Chen Hao Lo ◽  
Tao Li ◽  
Ayaz Muhammad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cancer Cells ◽  
Metastatic Prostate Cancer ◽  
Prostate Cancer Cell ◽  
Prostate Cancer Cells ◽  
Interleukin 28 ◽  
Selection Of

AbstractBone metastatic prostate cancer (PCa) promotes mesenchymal stem cell (MSC) recruitment and their differentiation into osteoblasts. However, the effects of bone-marrow derived MSCs on PCa cells are less explored. Here, we report MSC-derived interleukin-28 (IL-28) triggers prostate cancer cell apoptosis via IL-28 receptor alpha (IL-28Rα)-STAT1 signaling. However, chronic exposure to MSCs drives the selection of prostate cancer cells that are resistant to IL-28-induced apoptosis and therapeutics such as docetaxel. Further, MSC-selected/IL-28-resistant prostate cancer cells grow at accelerated rates in bone. Acquired resistance to apoptosis is PCa cell intrinsic, and is associated with a shift in IL-28Rα signaling via STAT1 to STAT3. Notably, STAT3 ablation or inhibition impairs MSC-selected prostate cancer cell growth and survival. Thus, bone marrow MSCs drive the emergence of therapy-resistant bone metastatic prostate cancer yet this can be disabled by targeting STAT3.

Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells

2021 ◽  
Vol 45 (5) ◽  
Author(s):  
Gisella Pérez ◽  
Fernanda López‑Moncada ◽  
Sebastián Indo ◽  
María Torres ◽  
Enrique Castellón ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cancer Cells ◽  
Prostate Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document